Heart & Cardiovascular Health

Even occasional marijuana use linked to 40% higher odds of stroke

As the legal landscape surrounding cannabis in the United States continues to evolve at a rapid pace, public health officials, cardiologists, and researchers are increasingly forced to re-evaluate the substance’s safety profile. For years, the public conversation surrounding marijuana legalization has primarily focused on criminal justice reform, tax revenue generation, and the management of chronic pain or mental health conditions. However, a major new epidemiological study presented at the American Heart Association’s Scientific Sessions 2026 suggests that the cardiovascular costs of this shifting cultural acceptance may be significantly higher than previously understood.

Examining data gathered from nearly half a million American adults, the preliminary research indicates that even occasional cannabis use is linked to higher odds of cardiovascular complications, including stroke, heart attacks, and coronary heart disease. Crucially, the heightened risk does not appear to scale linearly with consumption frequency, challenging long-held assumptions that light or infrequent use is inherently safe from a cardiological perspective.

The Evolving Landscape of American Cannabis Consumption

The backdrop of this new research is a dramatic, historic surge in American cannabis consumption. According to data highlighted by study author Dr. Aabha Divya, M.B.B.S., M.Ch., an assistant professor in the division of cardiothoracic surgery at the Tulane University School of Medicine in New Orleans, national consumption rates have spiked sharply over a remarkably short period.

In 2024, approximately 1 in 6 American adults reported using cannabis within the preceding month. This represents a staggering 51% increase compared to 2020, when only 1 in 10 adults reported similar usage. This acceleration coincides directly with a wave of legislative changes: as a growing number of states enact recreational legalization and commercial markets expand, access to high-potency cannabis flowers, concentrates, and edibles has become ubiquitous.

Historically, scientific inquiry into the health effects of cannabis has lagged behind commercial availability. While earlier research conducted between 2016 and 2020 successfully identified correlations between cannabis consumption and adverse cardiovascular outcomes—frequently noting that heavier use correlated with higher risk—the overall body of evidence remained inconsistent. Some studies suggested minimal risk for casual consumers, while others pointed to acute triggers for myocardial infarction or arrhythmias.

Motivated by these discrepancies and the rapidly expanding consumer base, Dr. Divya and her research colleagues sought to leverage a massive, contemporary dataset to clarify the relationship between marijuana use and heart health.

Methodology: Analyzing a Half-Million Lives

To conduct their investigation, the research team turned to the Behavioral Risk Factor Surveillance System (BRFSS). Maintained by the Centers for Disease Control and Prevention (CDC), the BRFSS is a rigorous, ongoing telephone survey that collects state-level data regarding health-related risk behaviors, chronic health conditions, and preventive services among American adults.

The researchers analyzed pooled survey data collected between 2020 and 2024. This timeframe was specifically chosen to capture the post-pandemic shifts in consumption habits and legalization milestones. The analysis drew from states that voluntarily elected to include an optional marijuana module in their annual BRFSS questionnaires—typically ranging between 16 and 24 participating states per year.

Ultimately, the study cohort comprised 442,906 American adults, with an average age of 49 years, evenly split between men and women. Participants were asked detailed questions regarding their cannabis habits over the preceding 30 days, including consumption methods such as smoking, vaping, or ingesting edibles like gummies and baked goods. They were also asked whether a licensed healthcare professional had ever formally diagnosed them with a cardiovascular condition, such as a heart attack, coronary heart disease, angina, or a stroke.

To ensure the statistical validity of their findings and to isolate the specific association of cannabis, the researchers rigorously controlled for a wide array of confounding variables. These included established cardiovascular risk factors such as traditional tobacco cigarette smoking, alcohol consumption, obesity, diabetes mellitus, chronic kidney disease, physical inactivity, age, sex, and socioeconomic indicators like education and income levels.

Unexpected Findings: The Threat of Occasional Use

One of the most startling and counterintuitive discoveries of the analysis was the nature of the dose-response relationship between cannabis and cardiovascular disease.

Prior to undertaking the study, the research team hypothesized a traditional, linear trajectory: as consumption frequency increased from occasional to heavy daily use, the statistical odds of developing heart disease or suffering a stroke would steadily climb. However, the data revealed a much more complex and concerning picture.

The analysis indicated that elevated odds of cardiovascular events were present even among individuals who reported infrequent or low-level cannabis consumption. Rather than a gentle slope of increasing risk, both low-use and heavy-use cohorts demonstrated significantly higher odds of cardiovascular complications compared to non-users. This revelation dismantles the comforting assumption held by many casual consumers that "occasional" or weekend use carries a negligible health penalty.

"We were surprised to find that the link between cannabis use and cardiovascular disease was not straightforward," Dr. Divya noted. "We expected that the chances of heart disease would gradually rise as people used cannabis more often, but that wasn’t the case. Both low-use and heavy-use groups had higher odds of developing heart disease."

Among the specific complications highlighted by the preliminary data, the association with stroke was particularly prominent. While the observational nature of the study precludes a definitive causal declaration—meaning researchers cannot state with absolute certainty that marijuana directly triggers strokes—the statistical correlation is strong enough to command the immediate attention of the medical community.

The Complicating Factor of Tobacco Co-Use

Evaluating the cardiovascular toll of cannabis has long been plagued by a significant methodological hurdle: co-consumption. A substantial portion of individuals who smoke cannabis also smoke traditional tobacco products. Because tobacco is a well-established, potent driver of atherosclerotic cardiovascular disease, isolating the distinct pathophysiological pathways of cannabis has historically challenged researchers.

Dr. Robert L. Page II, Pharm.D., M.S.P.H., FAHA, a professor in the departments of clinical pharmacy and physical medicine/rehabilitation at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, addressed this exact dilemma. Dr. Page led the writing group responsible for the American Heart Association’s landmark 2020 scientific statement on cannabis and cardiovascular health.

Though not directly involved in the new Tulane-led study, Dr. Page emphasized the gravity of the fresh findings.

"Unfortunately, many patients who use cannabis may also smoke tobacco, which completely clouds the issue when addressing atherosclerotic cardiovascular disease risk," Dr. Page explained. "In patients who use both, cannabis has always been considered an innocent bystander; however, this is not the case. This is the second observational study to suggest that cannabis exposure (without tobacco smoking) may be a potential risk factor for developing cardiovascular disease."

Dr. Page’s remarks point to a paradigm shift in cardiology. Cannabis is rapidly emerging not as an inert or benign recreational substance, but as an independent, major contributor to premature heart disease affecting both younger and older demographics. Consequently, the American Heart Association and allied experts are urging clinicians to systematically screen for cannabis use during routine patient intakes, treating it with the same clinical vigilance historically reserved for tobacco and excessive alcohol consumption.

Limitations of the Research

While the sheer scale of the 440,000-person cohort lends considerable weight to the findings, the study’s authors and independent experts emphasize that the research has notable limitations that must be considered when interpreting the data.

First, because the analysis relied on cross-sectional survey data captured at a single point in time, it establishes an association rather than causation. It remains within the realm of possibility that some individuals altered their consumption habits in response to pre-existing health diagnoses—for instance, patients reducing or ceasing cannabis use after experiencing a cardiac event, or conversely, individuals turning to cannabis for symptom management following a diagnosis.

Second, the study relied entirely on self-reported data. Self-reporting is inherently vulnerable to recall bias, social desirability bias, and underreporting, particularly regarding stigmatized or illicit behaviors. Furthermore, the survey questionnaires did not capture granular data regarding the precise chemical potency (such as THC concentration levels) or the absolute quantities of cannabis consumed by participants. A consumer utilizing low-potency flower is grouped alongside a consumer utilizing highly concentrated extracts, despite potential differences in physiological impact.

Finally, the geographical scope was limited to the subset of U.S. states that opted to include the optional marijuana module in the BRFSS between 2020 and 2024, meaning the findings may not be fully generalizable to populations in non-participating states or international jurisdictions with different cultural and regulatory environments.

Broader Implications and Future Outlook

The presentation of these findings at the American Heart Association’s Scientific Sessions 2026—held November 6 through 9 in Chicago—marks a critical juncture in modern public health policy and clinical practice.

As the commercial marijuana market continues its aggressive expansion across the United States, the traditional public health messaging surrounding the substance faces a rigorous stress test. While political and cultural debates frequently center on personal liberty and economic benefits, the biological reality unfolding in clinical research points to an under-recognized cardiovascular toll.

The implications for healthcare professionals are immediate. Cardiologists, primary care physicians, and emergency medicine practitioners must adapt their patient communication strategies. Just as clinicians routinely query patients about family heart history, diet, exercise, and cigarette smoking, inquiring about cannabis consumption—regardless of whether it is smoked, vaped, or ingested via edibles—must become a standard component of preventative cardiovascular care.

Ultimately, this large-scale analysis serves as a sobering reminder that physiological systems do not distinguish between legal markets and illicit ones. As researchers continue to untangle the complex mechanisms by which cannabinoids interact with the vascular and cardiac tissues, public health messaging will need to evolve, ensuring that consumers are fully informed of the potential cardiological risks associated with a substance rapidly weaving itself into the fabric of daily American life.

Related Articles

Back to top button
Kiat Sehatku

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.